Phaseline

Companies › Italfarmaco

Italfarmaco: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 3; Neurology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Givinostat Hydrochloride
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Polycythemia Vera; Duchenne Muscular Dystrophy; Chronic Myeloproliferative NeoplasmsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06093672Givinostat HydrochloridePhase 3Polycythemia VeraOncologyJul 2026
NCT01761968Givinostat HydrochloridePhase 2Chronic Myeloproliferative NeoplasmsOncologyDec 2026
NCT05933057Givinostat HydrochloridePhase 3Duchenne Muscular DystrophyNeurologyFeb 2028
NCT06769633Givinostat HydrochloridePhase 2Duchenne Muscular DystrophyNeurologyDec 2029
NCT03373968Givinostat HydrochloridePhase 2Duchenne Muscular DystrophyNeurologyDec 2029

Targets

HDAC (class I/II) (1)

Companies with the same targets

Xynomic Pharmaceuticals Jubilant Therapeutics Unravel Biosciences Great Novel Therapeutics Biotech & Medicals Daiichi Sankyo Chengdu Zenitar Biomedical Technology Acrotech Biopharma Novelwise Pharmaceutical Chipscreen Biosciences Novartis

Companies built like this

Great Novel Therapeutics Biotech & Medicals Acrotech Biopharma Xynomic Pharmaceuticals AB Science SK Life Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.